Aastrom Biosciences Inc (NASDAQ:ASTM)

CAPS Rating: 1 out of 5

The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.

Recs

1
Player Avatar wynharter (< 20) Submitted: 2/23/2007 1:35:31 PM : Outperform Start Price: $12.00 ASTM Score: -79.45

Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.

wyn harter

Featured Broker Partners


Advertisement